Provided by Tiger Trade Technology Pte. Ltd.

Trevi Therapeutics, Inc.

17.96
-0.2900-1.59%
Post-market: 18.150.1900+1.06%19:30 EDT
Volume:1.14M
Turnover:20.50M
Market Cap:2.55B
PE:-51.05
High:18.54
Open:18.44
Low:17.83
Close:18.25
52wk High:20.22
52wk Low:6.93
Shares:142.00M
Float Shares:118.00M
Volume Ratio:0.79
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3518
EPS(LYR):-0.3173
ROE:-19.66%
ROA:-13.82%
PB:7.93
PE(LYR):-56.60

Loading ...

Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)?

Simply Wall St.
·
Aug 14

Trevi Therapeutics (TRVI) Starts Key Cough Trials, Is It Still 29% Below Fair Value?

Simply Wall St.
·
Aug 08

Trevi Therapeutics, Inc. : Oppenheimer Raises Target Price to $25 from $24

THOMSON REUTERS
·
Aug 07

Trevi Therapeutics, Inc. : Raymond James Raises Target Price to $40 from $27

THOMSON REUTERS
·
Aug 07

Trevi Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Trevi Therapeutics Q2 Net Income USD -17.797 Million

Reuters
·
Aug 07

Trevi Therapeutics Q2 EPS USD -0.11

THOMSON REUTERS
·
Aug 07

Trevi Therapeutics Updates Financial Calendar with Upcoming Quarterly Results Call

Reuters
·
Jul 31

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

THOMSON REUTERS
·
Jul 31

Serina Therapeutics Appoints Trevi CCO Farrell Simon to Board

Reuters
·
Jul 23

Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Amneal Pharmaceuticals (AMRX) and Erasca (ERAS)

TIPRANKS
·
Jul 20

Trevi Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $24 from $21

THOMSON REUTERS
·
Jul 20

Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Brookdale Senior Living (BKD)

TIPRANKS
·
Jul 17

Trevi Therapeutics rises 10.4%

TIPRANKS
·
Jul 17

Trevi Therapeutics management attends BIO International Convention in June and July events

Reuters
·
Jun 17

Trevi Therapeutics shareholders approve increase in authorized common shares to 400 million

Reuters
·
Jun 05

Stock Track | Trevi Therapeutics Soars 5.27% in Intraday Trading After Stifel Raises Target Price to $30

Stock Track
·
May 08

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX)

TIPRANKS
·
May 08

Stock Track | Trevi Therapeutics Plummets 5.39% Intraday on Q1 Loss Worse Than Expected

Stock Track
·
May 06

Morgan Stanley Remains a Buy on Trevi Therapeutics (TRVI)

TIPRANKS
·
May 06